Last reviewed · How we verify
Rolufta
Rolufta, marketed by Fundacio Privada Mon Clinic Barcelona, is a drug with a key composition patent expiring in 2028. Its primary strength lies in its current market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the potential increase in competition post-2028, when the key patent expires.
At a glance
| Generic name | Rolufta |
|---|---|
| Also known as | LAMA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ANTES B+ Clinical Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |